

Kavita M Dhodapkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7462012/publications.pdf>

Version: 2024-02-01

28
papers

2,497
citations

471371

17
h-index

580701

25
g-index

28
all docs

28
docs citations

28
times ranked

4905
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>Oncolimmunology</i> , 2016, 5, e1071008.	2.1	545
2	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.4	362
3	Early B cell changes predict autoimmunity following combination immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 715-720.	3.9	298
4	Expansion of FOXP3 ^{high} regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. <i>Blood</i> , 2006, 108, 2655-2661.	0.6	291
5	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	2.3	140
6	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. <i>JCI Insight</i> , 2016, 1, e88955.	2.3	111
7	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. <i>JCI Insight</i> , 2019, 4, .	2.3	107
8	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. <i>Blood</i> , 2015, 125, 4042-4051.	0.6	103
9	ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 3905-3916.	3.9	81
10	Natural immunity to pluripotency antigen OCT4 in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8718-8723.	3.3	78
11	SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. <i>Oncolimmunology</i> , 2013, 2, e25205.	2.1	54
12	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. <i>JCI Insight</i> , 2020, 5, .	2.3	43
13	Nanoparticle-Mediated Combinatorial Targeting of Multiple Human Dendritic Cell (DC) Subsets Leads to Enhanced T Cell Activation via IL-15-Dependent DC Crosstalk. <i>Journal of Immunology</i> , 2014, 193, 2297-2305.	0.4	39
14	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	0.8	31
15	Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. , 2020, 8, e001066.		30
16	SOX2 immunity and tissue resident memory in children and young adults with glioma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 41-53.	1.4	27
17	Risk-associated alterations in marrow T cells in pediatric leukemia. <i>JCI Insight</i> , 2020, 5, .	2.3	23
18	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20

#	ARTICLE	IF	CITATIONS
19	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. Blood Cancer Discovery, 2021, 2, 9-12.	2.6	20
20	Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Advances, 2021, 5, 1535-1539.	2.5	17
21	Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade. Frontiers in Immunology, 2018, 9, 1655.	2.2	16
22	Tissue-resident memory-like T cells in tumor immunity: Clinical implications. Seminars in Immunology, 2020, 49, 101415.	2.7	15
23	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood Cancer Discovery, 2021, 2, 600-615.	2.6	15
24	Autoimmune complications of cancer immunotherapy. Current Opinion in Immunology, 2019, 61, 54-59.	2.4	9
25	Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7944-7945.	3.3	8
26	Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. Frontiers in Immunology, 2021, 12, 632564.	2.2	8
27	Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?. Frontiers in Immunology, 2019, 10, 2385.	2.2	6
28	Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia. , 2022, 10, e004774.		0